144 related articles for article (PubMed ID: 10726623)
1. Serum markers as prognostic factors in epithelial ovarian cancer: an overview.
Maggino T; Gadducci A
Eur J Gynaecol Oncol; 2000; 21(1):64-9. PubMed ID: 10726623
[TBL] [Abstract][Full Text] [Related]
2. [Ovarian cancers and CA 125 in 2006].
Lambaudie E; Collinet P; Vinatier D
Gynecol Obstet Fertil; 2006 Mar; 34(3):254-7. PubMed ID: 16529967
[TBL] [Abstract][Full Text] [Related]
3. Preoperative serum vascular endothelial growth factor (VEGF) in ovarian masses.
Tanir HM; Ozalp S; Yalcin OT; Colak O; Akcay A; Senses T
Eur J Gynaecol Oncol; 2003; 24(3-4):271-4. PubMed ID: 12807238
[TBL] [Abstract][Full Text] [Related]
4. [Clinical relevance of tumor markers in epithelial ovarian cancer].
Holubec L; Fínek J; Topolcan O; Bouda J; Rokyta Z
Ceska Gynekol; 2004 May; 69(3):225-8. PubMed ID: 15309999
[TBL] [Abstract][Full Text] [Related]
5. Markers supplementing CA 125 in ovarian cancer.
Stenman UH; Alfthan H; Vartiainen J; Lehtovirta P
Ann Med; 1995 Feb; 27(1):115-20. PubMed ID: 7741989
[TBL] [Abstract][Full Text] [Related]
6. OVX1, macrophage-colony stimulating factor, and CA-125-II as tumor markers for epithelial ovarian carcinoma: a critical appraisal.
van Haaften-Day C; Shen Y; Xu F; Yu Y; Berchuck A; Havrilesky LJ; de Bruijn HW; van der Zee AG; Bast RC; Hacker NF
Cancer; 2001 Dec; 92(11):2837-44. PubMed ID: 11753957
[TBL] [Abstract][Full Text] [Related]
7. Validity of colour and pulsed Doppler US and tumour marker CA 125 in differentiation between benign and malignant ovarian masses.
Antonić J; Rakar S
Eur J Gynaecol Oncol; 1996; 17(1):29-35. PubMed ID: 8750512
[TBL] [Abstract][Full Text] [Related]
8. Serum tumor markers in the management of ovarian, endometrial and cervical cancer.
Gadducci A; Cosio S; Carpi A; Nicolini A; Genazzani AR
Biomed Pharmacother; 2004 Jan; 58(1):24-38. PubMed ID: 14739059
[TBL] [Abstract][Full Text] [Related]
9. CA125 in ovarian cancer: European Group on Tumor Markers guidelines for clinical use.
Duffy MJ; Bonfrer JM; Kulpa J; Rustin GJ; Soletormos G; Torre GC; Tuxen MK; Zwirner M
Int J Gynecol Cancer; 2005; 15(5):679-91. PubMed ID: 16174214
[TBL] [Abstract][Full Text] [Related]
10. HE4, CA125, the Risk of Malignancy Algorithm and the Risk of Malignancy Index and complex pelvic masses - a prospective comparison in the pre-operative evaluation of pelvic masses in an Australian population.
Richards A; Herbst U; Manalang J; Pather S; Saidi S; Tejada-Berges T; Tan K; Williams P; Carter J
Aust N Z J Obstet Gynaecol; 2015 Oct; 55(5):493-7. PubMed ID: 26172511
[TBL] [Abstract][Full Text] [Related]
11. Role of tumour markers in monitoring epithelial ovarian cancer.
Meyer T; Rustin GJ
Br J Cancer; 2000 May; 82(9):1535-8. PubMed ID: 10789720
[TBL] [Abstract][Full Text] [Related]
12. Differentiating stage 1 epithelial ovarian cancer from benign ovarian tumours using a combination of tumour markers HE4, CA125, and CEA and patient's age.
Kondalsamy-Chennakesavan S; Hackethal A; Bowtell D; ; Obermair A
Gynecol Oncol; 2013 Jun; 129(3):467-71. PubMed ID: 23500084
[TBL] [Abstract][Full Text] [Related]
13. Pre-operative evaluation of ovarian tumors by risk of malignancy index, CA125 and ultrasound.
Arun-Muthuvel V; Jaya V
Asian Pac J Cancer Prev; 2014; 15(6):2929-32. PubMed ID: 24761927
[TBL] [Abstract][Full Text] [Related]
14. Tissue quantification of CA 125 in epithelial ovarian cancer.
de la Cuesta R; Maestro ML; Solana J; Vidart JA; Escudero M; Iglesias E; Valor R
Int J Biol Markers; 1999; 14(2):106-14. PubMed ID: 10399630
[TBL] [Abstract][Full Text] [Related]
15. Soluble tumor necrosis factor receptors and CA 125 in serum as markers for epithelial ovarian cancer.
Onsrud M; Shabana A; Austgulen R
Tumour Biol; 1996; 17(2):90-6. PubMed ID: 8658018
[TBL] [Abstract][Full Text] [Related]
16. Elevation of multiple serum markers in patients with stage I ovarian cancer.
Woolas RP; Xu FJ; Jacobs IJ; Yu YH; Daly L; Berchuck A; Soper JT; Clarke-Pearson DL; Oram DH; Bast RC
J Natl Cancer Inst; 1993 Nov; 85(21):1748-51. PubMed ID: 8411259
[TBL] [Abstract][Full Text] [Related]
17. [CA-125 antigen].
Zakrzewska I
Postepy Hig Med Dosw; 2002; 56(1):29-38. PubMed ID: 11987487
[TBL] [Abstract][Full Text] [Related]
18. Preoperative CA 125 levels: an independent prognostic factor for epithelial ovarian cancer.
Cooper BC; Sood AK; Davis CS; Ritchie JM; Sorosky JI; Anderson B; Buller RE
Obstet Gynecol; 2002 Jul; 100(1):59-64. PubMed ID: 12100804
[TBL] [Abstract][Full Text] [Related]
19. The prognostic and predictive value of combined HE4 and CA-125 in ovarian cancer patients.
Steffensen KD; Waldstrøm M; Brandslund I; Petzold M; Jakobsen A
Int J Gynecol Cancer; 2012 Nov; 22(9):1474-82. PubMed ID: 23095772
[TBL] [Abstract][Full Text] [Related]
20. Tumor markers in the management of patients with ovarian cancer.
Tuxen MK; Sölétormos G; Dombernowsky P
Cancer Treat Rev; 1995 May; 21(3):215-45. PubMed ID: 7656266
[No Abstract] [Full Text] [Related]
[Next] [New Search]
